ASCOT Adapt Trial

All Done!

A bit more to do?    Log in

The latest from the Spiral blog . . .

Thousands more patients gain access to second ground-breaking antiviral via Panoramic



A new anti-viral, Paxlovid, has recently been added to the PANORAMIC national study in the UK. 

Thousands more vulnerable people in England are now eligible to receive the UK’s second oral antiviral treatment for COVID-19. Paxlovid reduced the risk of hospitalisation or death by 88% in clinical trials and is already available directly through the NHS to highest-risk patients. The UK has procured more antivirals per head than any other country in Europe with over 4.98 million courses ordered so far.

The PANORAMIC national study is the UK’s fastest-ever recruiting clinical trial of its kind, run by the University of Oxford in close collaboration with GP hubs. It is already available directly through the NHS to those whose immune systems mean they are at higher risk of serious illness who test positive for the virus – including those who are immunocompromised, cancer patients or those with Down’s syndrome.

The PANORAMIC study makes antivirals available to a large number of patients while collecting further data on how the antivirals work where the majority of the adult population is vaccinated. It ensures antivirals are being used in the most effective way and is crucial in ensuring clinicians have the full information to prescribe antiviral treatments to patients in future

‘The addition of Paxlovid to the ground-breaking PANORAMIC study is an important milestone and will help us understand who benefits most from these treatments.’ - UK Health and Social Care Secretary Sajid Javid 

While vaccines remain the most important first line of defence, antivirals target the virus at an early stage, preventing progression to more severe, or even critical, symptoms.

The UK government has secured 2.75 million courses of Paxlovid (PF-07321332 and ritonavir), made by Pfizer. Those who enrol in the PANORAMIC study will be randomly allocated to receive either an antiviral treatment in addition to standard NHS care, or standard NHS care only.

As a study in our manifest, Spiral has now added Paxlovid to the PANORAMIC Trial platform. For Spiral and the team, this means lots of coding and extensions to the database to get everything ready for randomising. We’re so excited to see the growth in this study! Watch this space as we bring you more news on this aspect of the trial as it develops!


UK Government

Panoramic Trial


Follow us on Twitter


Like us on Facebook


About the trial

ASCOT ADAPT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

The trial aims to generate results quickly. After the trial begins, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial.

About the software

This is Spinnaker, a user friendly, bespoke application that helps researchers find answers to important medical questions. The team behind the platform can adapt the software to match your study and we are especially interested in doing this for novel trials.

Spinnaker is a cloud based, integrated software/database solution for randomising patients using any design methodology including response adaptive methods; backed up by an electronic data capture application that is intuitive and particular. The application also includes management functions to alert relevant people about events (e.g. SAE), to manage drug inventory and to report on progress.

You can read more on the Spinnaker website or contact Audrey on

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.

Made with love in New Zealand.